ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeted Screening for Taenia Solium Tapeworms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01296958
Recruitment Status : Completed
First Posted : February 16, 2011
Last Update Posted : October 24, 2014
Sponsor:
Collaborators:
Universidad Nacional Mayor de San Marcos
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Seth E O'Neal, MD MPH, Oregon Health and Science University

Brief Summary:
The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.

Condition or disease Intervention/treatment Phase
Taenia Solium Taeniasis Drug: Niclosamide Behavioral: Community education campaign Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1811 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Targeted Screening for Taenia Solium Tapeworms
Study Start Date : May 2011
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Targeted screening
Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
Drug: Niclosamide
Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
Active Comparator: Education
Community education about Taenia solium prevention.
Behavioral: Community education campaign
Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.



Primary Outcome Measures :
  1. Porcine seroprevalence [ Time Frame: Every 4 months ]

Secondary Outcome Measures :
  1. Intestinal tapeworm prevalence [ Time Frame: 16 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All community members are eligible

Exclusion Criteria:

  • Inability to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01296958


Locations
Peru
San Marcos University
Lima, Peru
Sponsors and Collaborators
Oregon Health and Science University
Universidad Nacional Mayor de San Marcos
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Seth E ONeal, MD MPH Oregon Health and Science University
Principal Investigator: Armando Gonzalez, DVM PhD San Marcos University School of Veterinary Medicine

Responsible Party: Seth E O'Neal, MD MPH, Assistant professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01296958     History of Changes
Other Study ID Numbers: 1R21NS069275-01 ( U.S. NIH Grant/Contract )
1R21NS069275-01 ( U.S. NIH Grant/Contract )
First Posted: February 16, 2011    Key Record Dates
Last Update Posted: October 24, 2014
Last Verified: October 2014

Keywords provided by Seth E O'Neal, MD MPH, Oregon Health and Science University:
Taenia solium
cysticercosis
neurocysticercosis

Additional relevant MeSH terms:
Taeniasis
Cestode Infections
Helminthiasis
Parasitic Diseases
Niclosamide
Anticestodal Agents
Antiplatyhelmintic Agents
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents
Antinematodal Agents